Abstract
Airway epithelium (AE) lines the conducting airways of the respiratory system and functions to maintain airway integrity by providing both a physical barrier to inhaled noxious agents and a mechanism for their clearance via the mucociliary escalator. Normal AE cells are relatively refractory to a number of apoptotic stimuli and survival mechanisms are in place to maintain the integrity of the epithelial barrier that is exposed to agents such as reactive oxygen species (ROS) and death receptor ligands secreted by immune cells during inflammation. When damage to AE does occur, there is increased AE apoptosis, such as in the airway damage that occurs in the chronically inflamed airways in diseases like asthma where rates of AE apoptosis can be increased many-fold. The usual treatment for persistent asthma in humans involves a combination of bronchodilator and inhaled corticosteroid; there is however a need to develop strategies to better control other aspects of the disease, including minimizing the ongoing damage to AE and consequent airway remodeling. Targeting of the major apoptosis-regulatory factors in AE may be one such strategy. Here we review what is known about apoptosis and its regulatory factors in normal AE and abnormalities in these factors in the inflamed airways of mice and humans.
Keywords: Airway epithelium, Apoptosis, Necrosis, Airway damage, Inflammation, Asthma, Caspases, Therapy
Current Molecular Pharmacology
Title: Apoptosis-Regulatory Factors as Potential Drug Targets in the Epithelium of Normal and Inflamed Airways
Volume: 1
Author(s): P. D. Zalewski and R. E. Ruffin
Affiliation:
Keywords: Airway epithelium, Apoptosis, Necrosis, Airway damage, Inflammation, Asthma, Caspases, Therapy
Abstract: Airway epithelium (AE) lines the conducting airways of the respiratory system and functions to maintain airway integrity by providing both a physical barrier to inhaled noxious agents and a mechanism for their clearance via the mucociliary escalator. Normal AE cells are relatively refractory to a number of apoptotic stimuli and survival mechanisms are in place to maintain the integrity of the epithelial barrier that is exposed to agents such as reactive oxygen species (ROS) and death receptor ligands secreted by immune cells during inflammation. When damage to AE does occur, there is increased AE apoptosis, such as in the airway damage that occurs in the chronically inflamed airways in diseases like asthma where rates of AE apoptosis can be increased many-fold. The usual treatment for persistent asthma in humans involves a combination of bronchodilator and inhaled corticosteroid; there is however a need to develop strategies to better control other aspects of the disease, including minimizing the ongoing damage to AE and consequent airway remodeling. Targeting of the major apoptosis-regulatory factors in AE may be one such strategy. Here we review what is known about apoptosis and its regulatory factors in normal AE and abnormalities in these factors in the inflamed airways of mice and humans.
Export Options
About this article
Cite this article as:
Zalewski D. P. and Ruffin E. R., Apoptosis-Regulatory Factors as Potential Drug Targets in the Epithelium of Normal and Inflamed Airways, Current Molecular Pharmacology 2008; 1 (1) . https://dx.doi.org/10.2174/1874467210801010038
DOI https://dx.doi.org/10.2174/1874467210801010038 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endogenous Repair System of Oxidative Damage of DNA
Current Chemical Biology Lipid-based Nano-phytomedicines for Disease Treatment and Theranostic Applications
Current Nanomedicine Antisense Technology: A Selective Tool for Gene Expression Regulation and Gene Targeting
Current Pharmaceutical Biotechnology Editorial: Premenstrual Syndrome and Dyspnea: Where is the Data?
Current Respiratory Medicine Reviews Policy and Adolescent Tobacco Use Prevention
Adolescent Psychiatry Hymenoptera Venom Proteins and Peptides for Diagnosis and Treatment of Venom Allergic Patients
Inflammation & Allergy - Drug Targets (Discontinued) Neuroimmune Interactions and Psychologycal Stress Induced by Cohabitation with a Sick Partner: A Review
Current Pharmaceutical Design Oxidative Stress and Cancer: The Role of Nrf2
Current Cancer Drug Targets Milestones in the Development of Chronic LPS-Induced Airway Disease
Current Respiratory Medicine Reviews Inflammatory Cellular Phenotypes and Molecular Mechanisms of Glucocorticoid Resistance in Patients with Bronchial Asthma
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Surface Energy Determined by Inverse Gas Chromatography as a Tool to Investigate Particulate Interactions in Dry Powder Inhalers
Current Pharmaceutical Design Hypersensitivity Reactions to Neuromuscular Blocking Agents
Current Pharmaceutical Design Eotaxin Receptor (CCR3) Antagonism in Asthma and Allergic Disease
Current Drug Targets - Inflammation & Allergy Peptide-Based Allergen Specific Immunotherapy for the Treatment of Allergic Disorders
Recent Patents on Inflammation & Allergy Drug Discovery The Role of microRNA-126 in Vascular Homeostasis
Current Vascular Pharmacology Experimental Approaches Towards Allergic Asthma Therapy-Murine Asthma Models
Recent Patents on Inflammation & Allergy Drug Discovery Personalized Therapies in Pediatric Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design The Inflammation Paradigm and Coronary Artery Disease: What Celsus, Virchow and Gene Knock Outs Have Taught Us
Cardiovascular & Hematological Disorders-Drug Targets The Potential of Ellagic Acid as a Possible Antimalarial Drug Candidate
Current Bioactive Compounds Selective Inhibition of Phosphodiesterases 4A, B, C and D Isoforms in Chronic Respiratory Diseases: Current and Future Evidences
Current Pharmaceutical Design